{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T05:11:24Z","timestamp":1794028284047,"version":"4.8.0"},"reference-count":178,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,8,3]],"date-time":"2023-08-03T00:00:00Z","timestamp":1691020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,8,3]],"date-time":"2023-08-03T00:00:00Z","timestamp":1691020800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Endocrinol"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1038\/s41574-023-00868-7","type":"journal-article","created":{"date-parts":[[2023,8,3]],"date-time":"2023-08-03T12:04:50Z","timestamp":1691064290000},"page":"581-599","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":76,"title":["An individualized approach to the management of Cushing disease"],"prefix":"10.1038","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9284-6289","authenticated-orcid":false,"given":"Maria","family":"Fleseriu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena V.","family":"Varlamov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6015-797X","authenticated-orcid":false,"given":"Jose M.","family":"Hinojosa-Amaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabienne","family":"Langlois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2355-3447","authenticated-orcid":false,"given":"Shlomo","family":"Melmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,3]]},"reference":[{"key":"868_CR1","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/S2213-8587(21)00235-7","volume":"9","author":"M Fleseriu","year":"2021","unstructured":"Fleseriu, M. et al. Consensus on diagnosis and management of Cushing\u2019s disease: a guideline update. Lancet Diabetes Endocrinol. 9, 847\u2013875 (2021).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"868_CR2","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1007\/s11102-022-01254-8","volume":"25","author":"PS Jones","year":"2022","unstructured":"Jones, P. S. & Swearingen, B. Pituitary surgery in Cushing\u2019s disease: first line treatment and role of reoperation. Pituitary 25, 713\u2013717 (2022).","journal-title":"Pituitary"},{"key":"868_CR3","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1056\/NEJMra1810772","volume":"382","author":"S Melmed","year":"2020","unstructured":"Melmed, S. Pituitary-tumor endocrinopathies. N. Engl. J. Med. 382, 937\u2013950 (2020).","journal-title":"N. Engl. J. Med."},{"key":"868_CR4","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s11102-019-00951-1","volume":"22","author":"O Ragnarsson","year":"2019","unstructured":"Ragnarsson, O. et al. The incidence of Cushing\u2019s disease: a nationwide Swedish study. Pituitary 22, 179\u2013186 (2019).","journal-title":"Pituitary"},{"key":"868_CR5","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s11102-014-0569-6","volume":"18","author":"MS Broder","year":"2015","unstructured":"Broder, M. S., Neary, M. P., Chang, E., Cherepanov, D. & Ludlam, W. H. Incidence of Cushing\u2019s syndrome and Cushing\u2019s disease in commercially-insured patients <65 years old in the United States. Pituitary 18, 283\u2013289 (2015).","journal-title":"Pituitary"},{"key":"868_CR6","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1210\/endrev\/bnac010","volume":"43","author":"S Melmed","year":"2022","unstructured":"Melmed, S. et al. Clinical biology of the pituitary adenoma. Endocr. Rev. 43, 1003\u20131037 (2022).","journal-title":"Endocr. Rev."},{"key":"868_CR7","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1210\/clinem\/dgac265","volume":"107","author":"P Limumpornpetch","year":"2022","unstructured":"Limumpornpetch, P. et al. The effect of endogenous Cushing syndrome on all-cause and cause-specific mortality. J. Clin. Endocrinol. Metab. 107, 2377\u20132388 (2022).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"868_CR8","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1210\/endrev\/bnab046","volume":"43","author":"LK Nieman","year":"2022","unstructured":"Nieman, L. K. Molecular derangements and the diagnosis of ACTH-dependent Cushing\u2019s syndrome. Endocr. Rev. 43, 852\u2013877 (2022).","journal-title":"Endocr. Rev."},{"key":"868_CR9","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s12022-022-09703-7","volume":"33","author":"SL Asa","year":"2022","unstructured":"Asa, S. L., Mete, O., Perry, A. & Osamura, R. Y. Overview of the 2022 WHO classification of pituitary tumors. Endocr. Pathol. 33, 6\u201326 (2022).","journal-title":"Endocr. Pathol."},{"key":"868_CR10","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/ng.3166","volume":"47","author":"M Reincke","year":"2015","unstructured":"Reincke, M. et al. Mutations in the deubiquitinase gene USP8 cause Cushing\u2019s disease. Nat. Genet. 47, 31\u201338 (2015).","journal-title":"Nat. Genet."},{"key":"868_CR11","doi-asserted-by":"publisher","first-page":"4712","DOI":"10.1172\/JCI60417","volume":"121","author":"H Fukuoka","year":"2011","unstructured":"Fukuoka, H. et al. EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas. J. Clin. Invest. 121, 4712\u20134721 (2011).","journal-title":"J. Clin. Invest."},{"key":"868_CR12","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.ccell.2019.11.002","volume":"37","author":"M Neou","year":"2020","unstructured":"Neou, M. et al. Pangenomic classification of pituitary neuroendocrine tumors. Cancer Cell 37, 123\u2013134 e125 (2020).","journal-title":"Cancer Cell"},{"key":"868_CR13","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s11102-020-01066-8","volume":"23","author":"A Stroud","year":"2020","unstructured":"Stroud, A. et al. Outcomes of pituitary surgery for Cushing\u2019s disease: a systematic review and meta-analysis. Pituitary 23, 595\u2013609 (2020).","journal-title":"Pituitary"},{"key":"868_CR14","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s11102-018-0904-4","volume":"21","author":"J Honegger","year":"2018","unstructured":"Honegger, J. & Grimm, F. The experience with transsphenoidal surgery and its importance to outcomes. Pituitary 21, 545\u2013555 (2018).","journal-title":"Pituitary"},{"key":"868_CR15","doi-asserted-by":"publisher","DOI":"10.1530\/EC-22-0349","volume":"12","author":"AH Zamanipoor Najafabadi","year":"2023","unstructured":"Zamanipoor Najafabadi, A. H. et al. Starting point for benchmarking outcomes and reporting of pituitary adenoma surgery within the European Reference Network on Rare Endocrine Conditions (Endo-ERN): results from a meta-analysis and survey study. Endocr. Connect. 12, e220349 (2023).","journal-title":"Endocr. Connect."},{"key":"868_CR16","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s11102-017-0838-2","volume":"20","author":"FF Casanueva","year":"2017","unstructured":"Casanueva, F. F. et al. Criteria for the definition of Pituitary Tumor Centers of Excellence (PTCOE): a pituitary society statement. Pituitary 20, 489\u2013498 (2017).","journal-title":"Pituitary"},{"key":"868_CR17","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1007\/s11102-022-01264-6","volume":"25","author":"M Couselo","year":"2022","unstructured":"Couselo, M., Frara, S., Giustina, A. & Casanueva, F. F. Pituitary Tumor Centers of Excellence for Cushing\u2019s disease. Pituitary 25, 772\u2013775 (2022).","journal-title":"Pituitary"},{"key":"868_CR18","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s11102-022-01239-7","volume":"25","author":"AB Yang","year":"2022","unstructured":"Yang, A. B., Henderson, F. Jr. & Schwartz, T. H. Surgical strategies in the treatment of MR-negative Cushing\u2019s disease: a systematic review and treatment algorithm. Pituitary 25, 551\u2013562 (2022).","journal-title":"Pituitary"},{"key":"868_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s12902-022-01069-5","volume":"22","author":"G Sharifi","year":"2022","unstructured":"Sharifi, G. et al. MRI-negative Cushing\u2019s disease: management strategy and outcomes in 15 cases utilizing a pure endoscopic endonasal approach. BMC Endocr. Disord. 22, 154 (2022).","journal-title":"BMC Endocr. Disord."},{"key":"868_CR20","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1210\/jc.2012-3943","volume":"98","author":"JJ Wind","year":"2013","unstructured":"Wind, J. J. et al. The lateralization accuracy of inferior petrosal sinus sampling in 501 patients with Cushing\u2019s disease. J. Clin. Endocrinol. Metab. 98, 2285\u20132293 (2013).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"868_CR21","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1227\/NEU.0b013e3182269d3f","volume":"58","author":"EH Oldfield","year":"2011","unstructured":"Oldfield, E. H. Surgical management of Cushing\u2019s disease: a personal perspective. Clin. Neurosurg. 58, 13\u201326 (2011).","journal-title":"Clin. Neurosurg."},{"key":"868_CR22","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.3390\/jcm11061558","volume":"11","author":"A Akirov","year":"2022","unstructured":"Akirov, A. et al. Clinical study and systematic review of pituitary microadenomas vs. macroadenomas in Cushing\u2019s disease: does size matter? J. Clin. Med. 11, 1558 (2022).","journal-title":"J. Clin. Med."},{"key":"868_CR23","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1007\/s11102-022-01226-y","volume":"25","author":"M Balomenaki","year":"2022","unstructured":"Balomenaki, M., Vassiliadi, D. A. & Tsagarakis, S. Cushing\u2019s disease: risk of recurrence following trans-sphenoidal surgery, timing and methods for evaluation. Pituitary 25, 718\u2013721 (2022).","journal-title":"Pituitary"},{"key":"868_CR24","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1055\/s-0031-1280682","volume":"21","author":"A Paluzzi","year":"2011","unstructured":"Paluzzi, A. et al. Endoscopic endonasal infrasellar approach to the sellar and suprasellar regions: technical note. Skull Base 21, 335\u2013342 (2011).","journal-title":"Skull Base"},{"key":"868_CR25","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1007\/s11102-018-0893-3","volume":"21","author":"LHA Broersen","year":"2018","unstructured":"Broersen, L. H. A. et al. Endoscopic vs. microscopic transsphenoidal surgery for Cushing\u2019s disease: a systematic review and meta-analysis. Pituitary 21, 524\u2013534 (2018).","journal-title":"Pituitary"},{"key":"868_CR26","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1590\/1806-9282.20210732","volume":"67","author":"T Zhang","year":"2021","unstructured":"Zhang, T., Zhang, B., Yuan, L., Song, Y. & Wang, F. Superiority of endoscopic transsphenoidal pituitary surgery to microscopic transseptal pituitary surgery for treatment of Cushing\u2019s disease. Rev. Assoc. Med. Bras. 67, 1687\u20131691 (2021).","journal-title":"Rev. Assoc. Med. Bras."},{"key":"868_CR27","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.wneu.2022.03.076","volume":"162","author":"M Sabahi","year":"2022","unstructured":"Sabahi, M. et al. MRI-negative Cushing\u2019s disease: a review on therapeutic management. World Neurosurg. 162, 126\u2013137 (2022).","journal-title":"World Neurosurg."},{"key":"868_CR28","doi-asserted-by":"publisher","first-page":"721","DOI":"10.3171\/2011.12.JNS11886","volume":"116","author":"SJ Monteith","year":"2012","unstructured":"Monteith, S. J., Starke, R. M., Jane, J. A. Jr. & Oldfield, E. H. Use of the histological pseudocapsule in surgery for Cushing disease: rapid postoperative cortisol decline predicting complete tumor resection. J. Neurosurg. 116, 721\u2013727 (2012).","journal-title":"J. Neurosurg."},{"key":"868_CR29","doi-asserted-by":"publisher","first-page":"404","DOI":"10.3171\/2016.1.JNS152119","volume":"126","author":"RR Lonser","year":"2017","unstructured":"Lonser, R. R., Nieman, L. & Oldfield, E. H. Cushing\u2019s disease: pathobiology, diagnosis, and management. J. Neurosurg. 126, 404\u2013417 (2017).","journal-title":"J. Neurosurg."},{"key":"868_CR30","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1007\/s12020-011-9499-5","volume":"40","author":"JS Lim","year":"2011","unstructured":"Lim, J. S., Lee, S. K., Kim, S. H., Lee, E. J. & Kim, S. H. Intraoperative multiple-staged resection and tumor tissue identification using frozen sections provide the best result for the accurate localization and complete resection of tumors in Cushing\u2019s disease. Endocrine 40, 452\u2013461 (2011).","journal-title":"Endocrine"},{"key":"868_CR31","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1007\/s00234-020-02431-x","volume":"62","author":"V Patel","year":"2020","unstructured":"Patel, V. et al. Ultra-high field magnetic resonance imaging for localization of corticotropin-secreting pituitary adenomas. Neuroradiology 62, 1051\u20131054 (2020).","journal-title":"Neuroradiology"},{"key":"868_CR32","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.3171\/2017.3.JNS163122","volume":"128","author":"Y Grober","year":"2018","unstructured":"Grober, Y., Grober, H., Wintermark, M., Jane, J. A. & Oldfield, E. H. Comparison of MRI techniques for detecting microadenomas in Cushing\u2019s disease. J. Neurosurg. 128, 1051\u20131057 (2018).","journal-title":"J. Neurosurg."},{"key":"868_CR33","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1111\/cen.12475","volume":"82","author":"Q Guo","year":"2015","unstructured":"Guo, Q., Young, W. F., Erickson, D. & Erickson, B. Usefulness of dynamic MRI enhancement measures for the diagnosis of ACTH-producing pituitary adenomas. Clin. Endocrinol. 82, 267\u2013273 (2015).","journal-title":"Clin. Endocrinol."},{"key":"868_CR34","doi-asserted-by":"publisher","first-page":"620","DOI":"10.3171\/2017.4.JNS17234","volume":"129","author":"GP Chatain","year":"2018","unstructured":"Chatain, G. P. et al. Potential utility of FLAIR in MRI-negative Cushing\u2019s disease. J. Neurosurg. 129, 620\u2013628 (2018).","journal-title":"J. Neurosurg."},{"key":"868_CR35","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s11102-022-01236-w","volume":"25","author":"WA Bashari","year":"2022","unstructured":"Bashari, W. A. et al. Modern imaging in Cushing\u2019s disease. Pituitary 25, 709\u2013712 (2022).","journal-title":"Pituitary"},{"key":"868_CR36","doi-asserted-by":"publisher","first-page":"1090144","DOI":"10.3389\/fendo.2022.1090144","volume":"13","author":"CH Koh","year":"2022","unstructured":"Koh, C. H. et al. The clinical outcomes of imaging modalities for surgical management Cushing\u2019s disease \u2014 a systematic review and meta-analysis. Front. Endocrinol. 13, 1090144 (2022).","journal-title":"Front. Endocrinol."},{"key":"868_CR37","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s12020-019-01944-7","volume":"65","author":"J Boyle","year":"2019","unstructured":"Boyle, J. et al. CRH stimulation improves 18F-FDG-PET detection of pituitary adenomas in Cushing\u2019s disease. Endocrine 65, 155\u2013165 (2019).","journal-title":"Endocrine"},{"key":"868_CR38","doi-asserted-by":"publisher","first-page":"101513","DOI":"10.1016\/j.beem.2021.101513","volume":"35","author":"R Senanayake","year":"2021","unstructured":"Senanayake, R. et al. New types of localization methods for adrenocorticotropic hormone-dependent Cushing\u2019s syndrome. Best Pract. Res. Clin. Endocrinol. Metab. 35, 101513 (2021).","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"868_CR39","doi-asserted-by":"publisher","first-page":"M107","DOI":"10.1530\/EJE-15-0616","volume":"173","author":"O Koulouri","year":"2015","unstructured":"Koulouri, O. et al. A role for 11C-methionine PET imaging in ACTH-dependent Cushing\u2019s syndrome. Eur. J. Endocrinol. 173, M107\u2013M120 (2015).","journal-title":"Eur. J. Endocrinol."},{"key":"868_CR40","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1007\/s11102-021-01160-5","volume":"24","author":"S Berkmann","year":"2021","unstructured":"Berkmann, S. et al. Selective resection of cushing microadenoma guided by preoperative hybrid 18-fluoroethyl-L-tyrosine and 11-C-methionine PET\/MRI. Pituitary 24, 878\u2013886 (2021).","journal-title":"Pituitary"},{"key":"868_CR41","doi-asserted-by":"publisher","first-page":"e1816","DOI":"10.1210\/clinem\/dgaa755","volume":"106","author":"R Walia","year":"2021","unstructured":"Walia, R. et al. Molecular imaging targeting corticotropin-releasing hormone receptor for corticotropinoma: a changing paradigm. J. Clin. Endocrinol. Metab. 106, e1816\u2013e1826 (2021).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"868_CR42","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1210\/jc.2009-1672","volume":"95","author":"E Valassi","year":"2010","unstructured":"Valassi, E. et al. Delayed remission after transsphenoidal surgery in patients with Cushing\u2019s disease. J. Clin. Endocrinol. Metab. 95, 601\u2013610 (2010).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"868_CR43","doi-asserted-by":"publisher","first-page":"e217","DOI":"10.1210\/clinem\/dgaa698","volume":"106","author":"Y Fan","year":"2021","unstructured":"Fan, Y. et al. Development of machine learning models for predicting postoperative delayed remission in patients with Cushing\u2019s disease. J. Clin. Endocrinol. Metab. 106, e217\u2013e231 (2021).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"868_CR44","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1210\/jc.2005-1204","volume":"91","author":"F Esposito","year":"2006","unstructured":"Esposito, F. et al. Clinical review: early morning cortisol levels as a predictor of remission after transsphenoidal surgery for Cushing\u2019s disease. J. Clin. Endocrinol. Metab. 91, 7\u201313 (2006).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"868_CR45","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1007\/s11102-012-0455-z","volume":"16","author":"N Hameed","year":"2013","unstructured":"Hameed, N. et al. Remission rate after transsphenoidal surgery in patients with pathologically confirmed Cushing\u2019s disease, the role of cortisol, ACTH assessment and immediate reoperation: a large single center experience. Pituitary 16, 452\u2013458 (2013).","journal-title":"Pituitary"},{"key":"868_CR46","doi-asserted-by":"publisher","first-page":"e94","DOI":"10.1210\/clinem\/dgaa773","volume":"106","author":"F Wang","year":"2021","unstructured":"Wang, F. et al. Postoperative day 1 morning cortisol value as a biomarker to predict long-term remission of cushing disease. J. Clin. Endocrinol. Metab. 106, e94\u2013e102 (2021).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"868_CR47","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1210\/jc.2011-0456","volume":"96","author":"JR Lindsay","year":"2011","unstructured":"Lindsay, J. R., Oldfield, E. H., Stratakis, C. A. & Nieman, L. K. The postoperative basal cortisol and CRH tests for prediction of long-term remission from Cushing\u2019s disease after transsphenoidal surgery. J. Clin. Endocrinol. Metab. 96, 2057\u20132064 (2011).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"868_CR48","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1530\/EJE-11-0424","volume":"165","author":"R Bou Khalil","year":"2011","unstructured":"Bou Khalil, R. et al. Sequential hormonal changes in 21 patients with recurrent Cushing\u2019s disease after successful pituitary surgery. Eur. J. Endocrinol. 165, 729\u2013737 (2011).","journal-title":"Eur. J. Endocrinol."},{"key":"868_CR49","doi-asserted-by":"publisher","first-page":"3770","DOI":"10.1210\/jc.2015-2107","volume":"100","author":"FG Amlashi","year":"2015","unstructured":"Amlashi, F. G. et al. Accuracy of late-night salivary cortisol in evaluating postoperative remission and recurrence in Cushing\u2019s disease. J. Clin. Endocrinol. Metab. 100, 3770\u20133777 (2015).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"868_CR50","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.4158\/EP161380.OR","volume":"22","author":"TB Carroll","year":"2016","unstructured":"Carroll, T. B., Javorsky, B. R. & Findling, J. W. Postsurgical recurrent Cushing disease: clinical benefit of early intervention in patients with normal urinary free cortisol. Endocr. Pract. 22, 1216\u20131223 (2016).","journal-title":"Endocr. Pract."},{"key":"868_CR51","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1007\/s12020-020-02432-z","volume":"70","author":"LT Braun","year":"2020","unstructured":"Braun, L. T. et al. Recurrence after pituitary surgery in adult Cushing\u2019s disease: a systematic review on diagnosis and treatment. Endocrine 70, 218\u2013231 (2020).","journal-title":"Endocrine"},{"key":"868_CR52","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1210\/jc.2017-02020","volume":"103","author":"Z Sandouk","year":"2018","unstructured":"Sandouk, Z. et al. Variability of late-night salivary cortisol in Cushing disease: a prospective study. J. Clin. Endocrinol. Metab. 103, 983\u2013990 (2018).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"868_CR53","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1111\/cen.12259","volume":"80","author":"S Petersenn","year":"2014","unstructured":"Petersenn, S. et al. High variability in baseline urinary free cortisol values in patients with Cushing\u2019s disease. Clin. Endocrinol. 80, 261\u2013269 (2014).","journal-title":"Clin. Endocrinol."},{"key":"868_CR54","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1530\/EJE-19-0770","volume":"182","author":"S Cambos","year":"2020","unstructured":"Cambos, S. et al. Persistent cortisol response to desmopressin predicts recurrence of Cushing\u2019s disease in patients with post-operative corticotropic insufficiency. Eur. J. Endocrinol. 182, 489\u2013498 (2020).","journal-title":"Eur. J. Endocrinol."},{"key":"868_CR55","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1530\/EC-19-0297","volume":"8","author":"P Abellan-Galiana","year":"2019","unstructured":"Abellan-Galiana, P. et al. Prognostic usefulness of ACTH in the postoperative period of Cushing\u2019s disease. Endocr. Connect. 8, 1262\u20131272 (2019).","journal-title":"Endocr. Connect."},{"key":"868_CR56","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1530\/ERC-22-0088","volume":"29","author":"A Albani","year":"2022","unstructured":"Albani, A. et al. Improved pasireotide response in USP8 mutant corticotroph tumours in vitro. Endocr. Relat. Cancer 29, 503\u2013511 (2022).","journal-title":"Endocr. Relat. Cancer"},{"key":"868_CR57","doi-asserted-by":"publisher","first-page":"E5","DOI":"10.3171\/2020.3.FOCUS2060","volume":"48","author":"M Zoli","year":"2020","unstructured":"Zoli, M. et al. Machine learning-based prediction of outcomes of the endoscopic endonasal approach in Cushing disease: is the future coming? Neurosurg. Focus 48, E5 (2020).","journal-title":"Neurosurg. Focus"},{"key":"868_CR58","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1007\/s11102-019-00985-5","volume":"22","author":"EY Nadezhdina","year":"2019","unstructured":"Nadezhdina, E. Y. et al. Prediction of recurrence and remission within 3 years in patients with Cushing disease after successful transnasal adenomectomy. Pituitary 22, 574\u2013580 (2019).","journal-title":"Pituitary"},{"key":"868_CR59","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s11102-021-01128-5","volume":"24","author":"S Shahrestani","year":"2021","unstructured":"Shahrestani, S. et al. Neural network modeling for prediction of recurrence, progression, and hormonal non-remission in patients following resection of functional pituitary adenomas. Pituitary 24, 523\u2013529 (2021).","journal-title":"Pituitary"},{"key":"868_CR60","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1210\/jc.2015-1818","volume":"100","author":"LK Nieman","year":"2015","unstructured":"Nieman, L. K. et al. Treatment of Cushing\u2019s syndrome: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 100, 2807\u20132831 (2015).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"868_CR61","doi-asserted-by":"publisher","first-page":"2558","DOI":"10.1056\/NEJMra062453","volume":"355","author":"S Melmed","year":"2006","unstructured":"Melmed, S. Medical progress: acromegaly. N. Engl. J. Med. 355, 2558\u20132573 (2006).","journal-title":"N. Engl. J. Med."},{"key":"868_CR62","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1530\/EJE-22-0317","volume":"187","author":"M Fleseriu","year":"2022","unstructured":"Fleseriu, M. et al. Long-term outcomes of osilodrostat in Cushing\u2019s disease: LINC 3 study extension. Eur. J. Endocrinol. 187, 531\u2013541 (2022).","journal-title":"Eur. J. Endocrinol."},{"key":"868_CR63","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1111\/cen.14081","volume":"91","author":"M Fleseriu","year":"2019","unstructured":"Fleseriu, M. et al. Long-term efficacy and safety of once-monthly pasireotide in Cushing\u2019s disease: a Phase III extension study. Clin. Endocrinol. 91, 776\u2013785 (2019).","journal-title":"Clin. Endocrinol."},{"key":"868_CR64","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1530\/EJE-22-0506","volume":"187","author":"M Fleseriu","year":"2022","unstructured":"Fleseriu, M. et al. Levoketoconazole treatment in endogenous Cushing\u2019s syndrome: extended evaluation of clinical, biochemical, and radiologic outcomes. Eur. J. Endocrinol. 187, 859\u2013871 (2022).","journal-title":"Eur. J. Endocrinol."},{"key":"868_CR65","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1530\/EJE-16-0662","volume":"176","author":"A Ferriere","year":"2017","unstructured":"Ferriere, A. et al. Cabergoline for Cushing\u2019s disease: a large retrospective multicenter study. Eur. J. Endocrinol. 176, 305\u2013314 (2017).","journal-title":"Eur. J. Endocrinol."},{"key":"868_CR66","doi-asserted-by":"publisher","first-page":"732240","DOI":"10.3389\/fendo.2021.732240","volume":"12","author":"J Simoes Correa Galendi","year":"2021","unstructured":"Simoes Correa Galendi, J., Correa Neto, A. N. S., Demetres, M., Boguszewski, C. L. & Nogueira, V. Effectiveness of medical treatment of Cushing\u2019s disease: a systematic review and meta-analysis. Front. Endocrinol. 12, 732240 (2021).","journal-title":"Front. Endocrinol."},{"key":"868_CR67","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1007\/s40618-021-01661-x","volume":"45","author":"R Pivonello","year":"2022","unstructured":"Pivonello, R., Pivonello, C., Simeoli, C., De Martino, M. C. & Colao, A. The dopaminergic control of Cushing\u2019s syndrome. J. Endocrinol. Invest. 45, 1297\u20131315 (2022).","journal-title":"J. Endocrinol. Invest."},{"key":"868_CR68","doi-asserted-by":"publisher","first-page":"101490","DOI":"10.1016\/j.beem.2021.101490","volume":"35","author":"EV Varlamov","year":"2021","unstructured":"Varlamov, E. V., Han, A. J. & Fleseriu, M. Updates in adrenal steroidogenesis inhibitors for Cushing\u2019s syndrome \u2014 a practical guide. Best Pract. Res. Clin. Endocrinol. Metab. 35, 101490 (2021).","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"868_CR69","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1210\/jc.2007-2734","volume":"93","author":"BM Biller","year":"2008","unstructured":"Biller, B. M. et al. Treatment of adrenocorticotropin-dependent Cushing\u2019s syndrome: a consensus statement. J. Clin. Endocrinol. Metab. 93, 2454\u20132462 (2008).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"868_CR70","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EJE-17-0796","volume":"178","author":"G Raverot","year":"2018","unstructured":"Raverot, G. et al. European Society of Endocrinology clinical practice guidelines for the management of aggressive pituitary tumours and carcinomas. Eur. J. Endocrinol. 178, G1\u2013G24 (2018).","journal-title":"Eur. J. Endocrinol."},{"key":"868_CR71","doi-asserted-by":"publisher","DOI":"10.1111\/jne.13169","volume":"34","author":"H Lasolle","year":"2022","unstructured":"Lasolle, H., Vasiljevic, A., Jouanneau, E., Ilie, M. D. & Raverot, G. Aggressive corticotroph tumors and carcinomas. J. Neuroendocrinol. 34, e13169 (2022).","journal-title":"J. Neuroendocrinol."},{"key":"868_CR72","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1056\/NEJMoa1105743","volume":"366","author":"A Colao","year":"2012","unstructured":"Colao, A. et al. A 12-month phase 3 study of pasireotide in Cushing\u2019s disease. N. Engl. J. Med. 366, 914\u2013924 (2012).","journal-title":"N. Engl. J. Med."},{"key":"868_CR73","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S2213-8587(17)30326-1","volume":"6","author":"A Lacroix","year":"2018","unstructured":"Lacroix, A. et al. Efficacy and safety of once-monthly pasireotide in Cushing\u2019s disease: a 12 month clinical trial. Lancet Diabetes Endocrinol. 6, 17\u201326 (2018).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"868_CR74","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1007\/s11102-019-00984-6","volume":"22","author":"L Manetti","year":"2019","unstructured":"Manetti, L. et al. Long-term safety and efficacy of subcutaneous pasireotide in patients with Cushing\u2019s disease: Interim results from a long-term real-world evidence study. Pituitary 22, 542\u2013551 (2019).","journal-title":"Pituitary"},{"key":"868_CR75","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1007\/s40618-020-01246-0","volume":"43","author":"A Lacroix","year":"2020","unstructured":"Lacroix, A. et al. Long-acting pasireotide improves clinical signs and quality of life in Cushing\u2019s disease: Results from a phase III study. J. Endocrinol. Invest. 43, 1613\u20131622 (2020).","journal-title":"J. Endocrinol. Invest."},{"key":"868_CR76","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1111\/cen.12431","volume":"81","author":"R Pivonello","year":"2014","unstructured":"Pivonello, R. et al. Pasireotide treatment significantly improves clinical signs and symptoms in patients with Cushing\u2019s disease: results from a phase III study. Clin. Endocrinol. 81, 408\u2013417 (2014).","journal-title":"Clin. Endocrinol."},{"key":"868_CR77","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1530\/EJE-19-0695","volume":"182","author":"J Newell-Price","year":"2020","unstructured":"Newell-Price, J. et al. Use of late-night salivary cortisol to monitor response to medical treatment in Cushing\u2019s disease. Eur. J. Endocrinol. 182, 207\u2013217 (2020).","journal-title":"Eur. J. Endocrinol."},{"key":"868_CR78","doi-asserted-by":"publisher","first-page":"935759","DOI":"10.3389\/fendo.2022.935759","volume":"13","author":"A Mondin","year":"2022","unstructured":"Mondin, A. et al. Pasireotide-induced shrinkage in GH and ACTH secreting pituitary adenoma: a systematic review and meta-analysis. Front. Endocrinol. 13, 935759 (2022).","journal-title":"Front. Endocrinol."},{"key":"868_CR79","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1007\/s11102-021-01161-4","volume":"24","author":"SL Samson","year":"2021","unstructured":"Samson, S. L. et al. Managing pasireotide-associated hyperglycemia: a randomized, open-label, phase IV study. Pituitary 24, 887\u2013903 (2021).","journal-title":"Pituitary"},{"key":"868_CR80","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1007\/s11102-022-01262-8","volume":"25","author":"R Pivonello","year":"2022","unstructured":"Pivonello, R., Simeoli, C., Di Paola, N. & Colao, A. Cushing\u2019s disease: adrenal steroidogenesis inhibitors. Pituitary 25, 726\u2013732 (2022).","journal-title":"Pituitary"},{"key":"868_CR81","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1210\/jc.2013-3628","volume":"99","author":"F Castinetti","year":"2014","unstructured":"Castinetti, F. et al. Ketoconazole in Cushing\u2019s disease: is it worth a try? J. Clin. Endocrinol. Metab. 99, 1623\u20131630 (2014).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"868_CR82","doi-asserted-by":"publisher","first-page":"1017331","DOI":"10.3389\/fendo.2022.1017331","volume":"13","author":"C Viecceli","year":"2022","unstructured":"Viecceli, C. et al. Evaluation of ketoconazole as a treatment for Cushing\u2019s disease in a retrospective cohort. Front. Endocrinol. 13, 1017331 (2022).","journal-title":"Front. Endocrinol."},{"key":"868_CR83","doi-asserted-by":"publisher","first-page":"L1","DOI":"10.1530\/EJE-18-0694","volume":"179","author":"M Ollivier","year":"2018","unstructured":"Ollivier, M., Haissaguerre, M., Ferriere, A. & Tabarin, A. Should we avoid using ketoconazole in patients with severe Cushing\u2019s syndrome and increased levels of liver enzymes? Eur. J. Endocrinol. 179, L1\u2013L2 (2018).","journal-title":"Eur. J. Endocrinol."},{"key":"868_CR84","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1530\/EJE-17-0886","volume":"178","author":"J Young","year":"2018","unstructured":"Young, J. et al. Hepatic safety of ketoconazole in Cushing\u2019s syndrome: results of a compassionate use programme in france. Eur. J. Endocrinol. 178, 447\u2013458 (2018).","journal-title":"Eur. J. Endocrinol."},{"key":"868_CR85","doi-asserted-by":"publisher","first-page":"e1618","DOI":"10.1210\/clinem\/dgaa989","volume":"106","author":"SG Creemers","year":"2021","unstructured":"Creemers, S. G. et al. Levoketoconazole, the 2S,4R enantiomer of ketoconazole, a new steroidogenesis inhibitor for Cushing\u2019s syndrome treatment. J. Clin. Endocrinol. Metab. 106, e1618\u2013e1630 (2021).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"868_CR86","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1007\/s11102-022-01263-7","volume":"25","author":"R Pivonello","year":"2022","unstructured":"Pivonello, R. et al. Levoketoconazole in the treatment of patients with endogenous Cushing\u2019s syndrome: a double-blind, placebo-controlled, randomized withdrawal study (LOGICS). Pituitary 25, 911\u2013926 (2022).","journal-title":"Pituitary"},{"key":"868_CR87","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/S2213-8587(19)30313-4","volume":"7","author":"M Fleseriu","year":"2019","unstructured":"Fleseriu, M. et al. Efficacy and safety of levoketoconazole in the treatment of endogenous Cushing\u2019s syndrome (SONICS): a phase 3, multicentre, open-label, single-arm trial. Lancet Diabetes Endocrinol. 7, 855\u2013865 (2019).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"868_CR88","doi-asserted-by":"publisher","first-page":"595894","DOI":"10.3389\/fendo.2021.595894","volume":"12","author":"R Pivonello","year":"2021","unstructured":"Pivonello, R. et al. Levoketoconazole in the treatment of patients with Cushing\u2019s syndrome and diabetes mellitus: results from the SONICS phase 3 study. Front. Endocrinol. 12, 595894 (2021).","journal-title":"Front. Endocrinol."},{"key":"868_CR89","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/S2213-8587(20)30240-0","volume":"8","author":"R Pivonello","year":"2020","unstructured":"Pivonello, R. et al. Efficacy and safety of osilodrostat in patients with Cushing\u2019s disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase. Lancet Diabetes Endocrinol. 8, 748\u2013761 (2020).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"868_CR90","doi-asserted-by":"publisher","first-page":"e2882","DOI":"10.1210\/clinem\/dgac178","volume":"107","author":"M Gadelha","year":"2022","unstructured":"Gadelha, M. et al. Randomized trial of osilodrostat for the treatment of cushing disease. J. Clin. Endocrinol. Metab. 107, e2882\u2013e2895 (2022).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"868_CR91","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1007\/s11102-022-01280-6","volume":"25","author":"M Fleseriu","year":"2022","unstructured":"Fleseriu, M. et al. Long-term efficacy and safety of osilodrostat in Cushing\u2019s disease: final results from a Phase II study with an optional extension phase (LINC 2). Pituitary 25, 959\u2013970 (2022).","journal-title":"Pituitary"},{"key":"868_CR92","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s11102-022-01218-y","volume":"25","author":"X He","year":"2022","unstructured":"He, X., Findling, J. W. & Auchus, R. J. Glucocorticoid withdrawal syndrome following treatment of endogenous Cushing syndrome. Pituitary 25, 393\u2013403 (2022).","journal-title":"Pituitary"},{"key":"868_CR93","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s11102-020-01097-1","volume":"24","author":"C Fontaine-Sylvestre","year":"2021","unstructured":"Fontaine-Sylvestre, C., Letourneau-Guillon, L., Moumdjian, R. A., Berthelet, F. & Lacroix, A. Corticotroph tumor progression during long-term therapy with osilodrostat in a patient with persistent Cushing\u2019s disease. Pituitary 24, 207\u2013215 (2021).","journal-title":"Pituitary"},{"key":"868_CR94","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1530\/EJE-22-0320","volume":"187","author":"HF Nowotny","year":"2022","unstructured":"Nowotny, H. F. et al. 11-Oxygenated C19 steroids are the predominant androgens responsible for hyperandrogenemia in Cushing\u2019s disease. Eur. J. Endocrinol. 187, 663\u2013673 (2022).","journal-title":"Eur. J. Endocrinol."},{"key":"868_CR95","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1530\/EJE-22-0208","volume":"187","author":"F Bonnet-Serrano","year":"2022","unstructured":"Bonnet-Serrano, F. et al. Differences in the spectrum of steroidogenic enzyme inhibition between osilodrostat and metyrapone in ACTH-dependent Cushing syndrome patients. Eur. J. Endocrinol. 187, 315\u2013322 (2022).","journal-title":"Eur. J. Endocrinol."},{"key":"868_CR96","doi-asserted-by":"publisher","first-page":"4146","DOI":"10.1210\/jc.2015-2616","volume":"100","author":"E Daniel","year":"2015","unstructured":"Daniel, E. et al. Effectiveness of metyrapone in treating Cushing\u2019s syndrome: a retrospective multicenter study in 195 patients. J. Clin. Endocrinol. Metab. 100, 4146\u20134154 (2015).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"868_CR97","doi-asserted-by":"publisher","first-page":"A515","DOI":"10.1210\/jendso\/bvab048.1053","volume":"5","author":"LK Nieman","year":"2021","unstructured":"Nieman, L. K. et al. Metyrapone treatment in endogenous Cushing\u2019s syndrome: results at week 12 from PROMPT, a prospective international multicenter, open-label, phase III\/IV study. J. Endocr. Soc. 5, A515 (2021).","journal-title":"J. Endocr. Soc."},{"key":"868_CR98","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1530\/EJE-20-0380","volume":"183","author":"SM Constantinescu","year":"2020","unstructured":"Constantinescu, S. M. et al. Etomidate infusion at low doses is an effective and safe treatment for severe Cushing\u2019s syndrome outside intensive care. Eur. J. Endocrinol. 183, 161\u2013167 (2020).","journal-title":"Eur. J. Endocrinol."},{"key":"868_CR99","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1530\/EJE-12-0358","volume":"167","author":"C Baudry","year":"2012","unstructured":"Baudry, C. et al. Efficiency and tolerance of mitotane in Cushing\u2019s disease in 76 patients from a single center. Eur. J. Endocrinol. 167, 473\u2013481 (2012).","journal-title":"Eur. J. Endocrinol."},{"key":"868_CR100","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1210\/jc.2011-3350","volume":"97","author":"M Fleseriu","year":"2012","unstructured":"Fleseriu, M. et al. Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing\u2019s syndrome. J. Clin. Endocrinol. Metab. 97, 2039\u20132049 (2012).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"868_CR101","doi-asserted-by":"publisher","first-page":"3718","DOI":"10.1210\/jc.2014-1843","volume":"99","author":"M Fleseriu","year":"2014","unstructured":"Fleseriu, M. et al. Changes in plasma ACTH levels and corticotroph tumor size in patients with Cushing\u2019s disease during long-term treatment with the glucocorticoid receptor antagonist mifepristone. J. Clin. Endocrinol. Metab. 99, 3718\u20133727 (2014).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"868_CR102","doi-asserted-by":"publisher","first-page":"2796","DOI":"10.1210\/jc.2011-0536","volume":"96","author":"P Kamenicky","year":"2011","unstructured":"Kamenicky, P. et al. Mitotane, metyrapone, and ketoconazole combination therapy as an alternative to rescue adrenalectomy for severe ACTH-dependent Cushing\u2019s syndrome. J. Clin. Endocrinol. Metab. 96, 2796\u20132804 (2011).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"868_CR103","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1111\/j.1365-2265.2012.04424.x","volume":"77","author":"E Valassi","year":"2012","unstructured":"Valassi, E., Crespo, I., Gich, I., Rodriguez, J. & Webb, S. M. A reappraisal of the medical therapy with steroidogenesis inhibitors in Cushing\u2019s syndrome. Clin. Endocrinol. 77, 735\u2013742 (2012).","journal-title":"Clin. Endocrinol."},{"key":"868_CR104","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1056\/NEJMc1000094","volume":"362","author":"RA Feelders","year":"2010","unstructured":"Feelders, R. A. et al. Pasireotide alone or with cabergoline and ketoconazole in Cushing\u2019s disease. N. Engl. J. Med. 362, 1846\u20131848 (2010).","journal-title":"N. Engl. J. Med."},{"key":"868_CR105","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s11102-009-0209-8","volume":"13","author":"L Vilar","year":"2010","unstructured":"Vilar, L. et al. Effectiveness of cabergoline in monotherapy and combined with ketoconazole in the management of Cushing\u2019s disease. Pituitary 13, 123\u2013129 (2010).","journal-title":"Pituitary"},{"key":"868_CR106","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s11102-013-0475-3","volume":"17","author":"M Barbot","year":"2014","unstructured":"Barbot, M. et al. Combination therapy for Cushing\u2019s disease: effectiveness of two schedules of treatment: should we start with cabergoline or ketoconazole? Pituitary 17, 109\u2013117 (2014).","journal-title":"Pituitary"},{"key":"868_CR107","doi-asserted-by":"crossref","first-page":"i1","DOI":"10.1093\/edrv\/38.supp.1","volume":"38","author":"R Feelders","year":"2017","unstructured":"Feelders, R. et al. Prospective phase ii study (CAPACITY) of pasireotide monotherapy or in combination with cabergoline in patients with Cushing\u2019s disease (Poster). Endocr. Rev. 38 (Suppl. 1), i1\u2013i1431 (2017).","journal-title":"Endocr. Rev."},{"key":"868_CR108","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/s11102-018-0897-z","volume":"21","author":"LHA Broersen","year":"2018","unstructured":"Broersen, L. H. A., Jha, M., Biermasz, N. R., Pereira, A. M. & Dekkers, O. M. Effectiveness of medical treatment for Cushing\u2019s syndrome: a systematic review and meta-analysis. Pituitary 21, 631\u2013641 (2018).","journal-title":"Pituitary"},{"key":"868_CR109","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1007\/s11102-022-01238-8","volume":"25","author":"MR Gadelha","year":"2022","unstructured":"Gadelha, M. R., Wildemberg, L. E. & Shimon, I. Pituitary acting drugs: cabergoline and pasireotide. Pituitary 25, 722\u2013725 (2022).","journal-title":"Pituitary"},{"key":"868_CR110","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1007\/s40618-020-01335-0","volume":"43","author":"F Gatto","year":"2020","unstructured":"Gatto, F., Arvigo, M. & Ferone, D. Somatostatin receptor expression and patients\u2019 response to targeted medical treatment in pituitary tumors: evidences and controversies. J. Endocrinol. Invest. 43, 1543\u20131553 (2020).","journal-title":"J. Endocrinol. Invest."},{"key":"868_CR111","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1002\/jcph.400","volume":"54","author":"HK Greenblatt","year":"2014","unstructured":"Greenblatt, H. K. & Greenblatt, D. J. Liver injury associated with ketoconazole: review of the published evidence. J. Clin. Pharmacol. 54, 1321\u20131329 (2014).","journal-title":"J. Clin. Pharmacol."},{"key":"868_CR112","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1007\/s12020-016-0978-6","volume":"54","author":"JW Findling","year":"2016","unstructured":"Findling, J. W. et al. Late-night salivary cortisol may be valuable for assessing treatment response in patients with Cushing\u2019s disease: 12-month, phase III pasireotide study. Endocrine 54, 516\u2013523 (2016).","journal-title":"Endocrine"},{"key":"868_CR113","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1210\/clinem\/dgac691","volume":"108","author":"A Dormoy","year":"2023","unstructured":"Dormoy, A. et al. Efficacy and safety of osilodrostat in paraneoplastic Cushing\u2019s syndrome: a real-world multicenter study in France. J. Clin. Endocrinol. Metab. 108, 1475\u20131487 (2023).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"868_CR114","doi-asserted-by":"publisher","first-page":"L13","DOI":"10.1530\/EJE-21-0147","volume":"184","author":"L Bessiene","year":"2021","unstructured":"Bessiene, L. et al. Rapid control of severe ectopic Cushing\u2019s syndrome by oral osilodrostat monotherapy. Eur. J. Endocrinol. 184, L13\u2013L15 (2021).","journal-title":"Eur. J. Endocrinol."},{"key":"868_CR115","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1530\/EJE-17-0997","volume":"178","author":"E Valassi","year":"2018","unstructured":"Valassi, E. et al. Preoperative medical treatment in Cushing\u2019s syndrome: frequency of use and its impact on postoperative assessment: data from ERCUSYN. Eur. J. Endocrinol. 178, 399\u2013409 (2018).","journal-title":"Eur. J. Endocrinol."},{"key":"868_CR116","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1210\/clinem\/dgac588","volume":"108","author":"NA Liu","year":"2023","unstructured":"Liu, N. A. et al. Treatment of Cushing\u2019s disease with pituitary-targeting seliciclib. J. Clin. Endocrinol. Metab. 108, 726\u2013735 (2023).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"868_CR117","unstructured":"Krasner, A. et al. Inhibition of Basal and ACTH-Stimulated Cortisol Secretion in Humans Using an Oral, Nonpeptide ACTH Antagonist (CRN04894) ENDO 2022. Poster presentation (2022)."},{"key":"868_CR118","first-page":"1","volume":"158","author":"AL Feldhaus","year":"2017","unstructured":"Feldhaus, A. L. et al. ALD1613, a novel long-acting monoclonal antibody to control ACTH-driven pharmacology. Endocrinology 158, 1\u20138 (2017).","journal-title":"Endocrinology"},{"key":"868_CR119","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1097\/MED.0000000000000344","volume":"24","author":"A Ben-Shlomo","year":"2017","unstructured":"Ben-Shlomo, A. & Cooper, O. Role of tyrosine kinase inhibitors in the treatment of pituitary tumours: From bench to bedside. Curr. Opin. Endocrinol. Diabetes Obes. 24, 301\u2013305 (2017).","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"key":"868_CR120","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1007\/s11102-014-0607-4","volume":"18","author":"A Sugiyama","year":"2015","unstructured":"Sugiyama, A. et al. Inhibition of heat shock protein 90 decreases ACTH production and cell proliferation in AtT-20 cells. Pituitary 18, 542\u2013553 (2015).","journal-title":"Pituitary"},{"key":"868_CR121","doi-asserted-by":"publisher","first-page":"662865","DOI":"10.3389\/fendo.2021.662865","volume":"12","author":"R Pivonello","year":"2021","unstructured":"Pivonello, R. et al. Relacorilant, a selective glucocorticoid receptor modulator, induces clinical improvements in patients with Cushing syndrome: results from a prospective, open-label phase 2 study. Front. Endocrinol. 12, 662865 (2021).","journal-title":"Front. Endocrinol."},{"key":"868_CR122","doi-asserted-by":"publisher","first-page":"e3865","DOI":"10.1210\/clinem\/dgab450","volume":"106","author":"S Oda","year":"2021","unstructured":"Oda, S. et al. An open-label phase I\/IIA clinical trial of 11BETA-HSD1 inhibitor for Cushing\u2019s syndrome and autonomous cortisol secretion. J. Clin. Endocrinol. Metab. 106, e3865\u2013e3880 (2021).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"868_CR123","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1007\/s11102-022-01234-y","volume":"25","author":"L Katznelson","year":"2022","unstructured":"Katznelson, L. Role of radiation in the treatment of Cushing disease. Pituitary 25, 740\u2013742 (2022).","journal-title":"Pituitary"},{"key":"868_CR124","doi-asserted-by":"publisher","first-page":"101514","DOI":"10.1016\/j.beem.2021.101514","volume":"35","author":"ML Gheorghiu","year":"2021","unstructured":"Gheorghiu, M. L. Updates in the outcomes of radiation therapy for Cushing\u2019s disease. Best Pract. Res. Clin. Endocrinol. Metab. 35, 101514 (2021).","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"868_CR125","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s11102-019-00992-6","volume":"22","author":"AD Sherry","year":"2019","unstructured":"Sherry, A. D. et al. Outcomes of stereotactic radiosurgery and hypofractionated stereotactic radiotherapy for refractory Cushing\u2019s disease. Pituitary 22, 607\u2013613 (2019).","journal-title":"Pituitary"},{"key":"868_CR126","doi-asserted-by":"publisher","first-page":"4284","DOI":"10.1210\/jc.2017-01385","volume":"102","author":"GU Mehta","year":"2017","unstructured":"Mehta, G. U. et al. Stereotactic radiosurgery for Cushing disease: results of an international, multicenter study. J. Clin. Endocrinol. Metab. 102, 4284\u20134291 (2017).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"868_CR127","doi-asserted-by":"publisher","first-page":"801","DOI":"10.3171\/2021.2.JNS204440","volume":"136","author":"D Mathieu","year":"2022","unstructured":"Mathieu, D. et al. Stereotactic radiosurgery for secretory pituitary adenomas: systematic review and international stereotactic radiosurgery society practice recommendations. J. Neurosurg. 136, 801\u2013812 (2022).","journal-title":"J. Neurosurg."},{"key":"868_CR128","doi-asserted-by":"publisher","first-page":"807","DOI":"10.3171\/2019.12.JNS192836","volume":"134","author":"A Bunevicius","year":"2020","unstructured":"Bunevicius, A. et al. Early versus late Gamma Knife radiosurgery for Cushing\u2019s disease after prior resection: results of an international, multicenter study. J. Neurosurg. 134, 807\u2013815 (2020).","journal-title":"J. Neurosurg."},{"key":"868_CR129","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1227\/NEU.0000000000000425","volume":"75","author":"CC Lee","year":"2014","unstructured":"Lee, C. C. et al. Whole-sellar stereotactic radiosurgery for functioning pituitary adenomas. Neurosurgery 75, 227\u2013237 (2014).","journal-title":"Neurosurgery"},{"key":"868_CR130","doi-asserted-by":"publisher","first-page":"e670","DOI":"10.1016\/j.wneu.2018.05.067","volume":"116","author":"MJ Shepard","year":"2018","unstructured":"Shepard, M. J. et al. Technique of whole-sellar stereotactic radiosurgery for cushing disease: results from a multicenter. Int. Cohort Study World Neurosurg. 116, e670\u2013e679 (2018).","journal-title":"Int. Cohort Study World Neurosurg."},{"key":"868_CR131","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1227\/neu.0000000000002347","volume":"92","author":"N Ironside","year":"2023","unstructured":"Ironside, N. et al. Effects of neuroanatomic structural distances on pituitary function after stereotactic radiosurgery: a multicenter study. Neurosurgery 92, 1035\u20131042 (2023).","journal-title":"Neurosurgery"},{"key":"868_CR132","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1210\/jc.2016-3402","volume":"102","author":"P Burman","year":"2017","unstructured":"Burman, P., van Beek, A. P., Biller, B. M., Camacho-Hubner, C. & Mattsson, A. F. Radiotherapy, especially at young age, increases the risk for de novo brain tumors in patients treated for pituitary\/sellar lesions. J. Clin. Endocrinol. Metab. 102, 1051\u20131058 (2017).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"868_CR133","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1210\/jc.2014-3697","volume":"100","author":"NC van Varsseveld","year":"2015","unstructured":"van Varsseveld, N. C. et al. Cerebrovascular events, secondary intracranial tumors, and mortality after radiotherapy for nonfunctioning pituitary adenomas: a subanalysis from the Dutch National Registry of Growth Hormone Treatment in Adults. J. Clin. Endocrinol. Metab. 100, 1104\u20131112 (2015).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"868_CR134","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/S2213-8587(22)00160-7","volume":"10","author":"R Hamblin","year":"2022","unstructured":"Hamblin, R. et al. Risk of second brain tumour after radiotherapy for pituitary adenoma or craniopharyngioma: a retrospective, multicentre, cohort study of 3679 patients with long-term imaging surveillance. Lancet Diabetes Endocrinol. 10, 581\u2013588 (2022).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"868_CR135","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/S1470-2045(18)30659-4","volume":"20","author":"A Wolf","year":"2019","unstructured":"Wolf, A. et al. Risk of radiation-associated intracranial malignancy after stereotactic radiosurgery: a retrospective, multicentre, cohort study. Lancet Oncol. 20, 159\u2013164 (2019).","journal-title":"Lancet Oncol."},{"key":"868_CR136","doi-asserted-by":"publisher","first-page":"M23","DOI":"10.1530\/EJE-15-0265","volume":"173","author":"M Reincke","year":"2015","unstructured":"Reincke, M. et al. A critical reappraisal of bilateral adrenalectomy for ACTH-dependent Cushing\u2019s syndrome. Eur. J. Endocrinol. 173, M23\u2013M32 (2015).","journal-title":"Eur. J. Endocrinol."},{"key":"868_CR137","doi-asserted-by":"publisher","first-page":"3939","DOI":"10.1210\/jc.2013-1470","volume":"98","author":"K Ritzel","year":"2013","unstructured":"Ritzel, K. et al. Clinical review: outcome of bilateral adrenalectomy in Cushing\u2019s syndrome: a systematic review. J. Clin. Endocrinol. Metab. 98, 3939\u20133948 (2013).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"868_CR138","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1007\/s11102-022-01260-w","volume":"25","author":"J Bertherat","year":"2022","unstructured":"Bertherat, J. Cushing\u2019s disease: role of bilateral adrenalectomy. Pituitary 25, 743\u2013745 (2022).","journal-title":"Pituitary"},{"key":"868_CR139","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1007\/s00423-022-02568-8","volume":"407","author":"J Reibetanz","year":"2022","unstructured":"Reibetanz, J. et al. Differences in morbidity and mortality between unilateral adrenalectomy for adrenal Cushing\u2019s syndrome and bilateral adrenalectomy for therapy refractory extra-adrenal Cushing\u2019s syndrome. Langenbecks Arch. Surg. 407, 2481\u20132488 (2022).","journal-title":"Langenbecks Arch. Surg."},{"key":"868_CR140","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1007\/s11102-021-01158-z","volume":"24","author":"E Papakokkinou","year":"2021","unstructured":"Papakokkinou, E. et al. Prevalence of Nelson\u2019s syndrome after bilateral adrenalectomy in patients with cushing\u2019s disease: a systematic review and meta-analysis. Pituitary 24, 797\u2013809 (2021).","journal-title":"Pituitary"},{"key":"868_CR141","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1007\/s11102-020-01047-x","volume":"23","author":"L Das","year":"2020","unstructured":"Das, L. et al. ACTH increment post total bilateral adrenalectomy for Cushing\u2019s disease: a consistent biosignature for predicting Nelson\u2019s syndrome. Pituitary 23, 488\u2013497 (2020).","journal-title":"Pituitary"},{"key":"868_CR142","doi-asserted-by":"publisher","first-page":"P1","DOI":"10.1530\/EJE-20-1088","volume":"184","author":"M Reincke","year":"2021","unstructured":"Reincke, M. et al. Corticotroph tumor progression after bilateral adrenalectomy (Nelson\u2019s syndrome): systematic review and expert consensus recommendations. Eur. J. Endocrinol. 184, P1\u2013P16 (2021).","journal-title":"Eur. J. Endocrinol."},{"key":"868_CR143","doi-asserted-by":"publisher","first-page":"bvz033","DOI":"10.1210\/jendso\/bvz033","volume":"4","author":"MG Suarez","year":"2020","unstructured":"Suarez, M. G. et al. Hypercoagulability in Cushing syndrome, prevalence of thrombotic events: a large, single-center, retrospective study. J. Endocr. Soc. 4, bvz033 (2020).","journal-title":"J. Endocr. Soc."},{"key":"868_CR144","doi-asserted-by":"publisher","first-page":"R207","DOI":"10.1530\/EJE-20-1309","volume":"184","author":"EV Varlamov","year":"2021","unstructured":"Varlamov, E. V., Langlois, F., Vila, G. & Fleseriu, M. Management of endocrine disease: cardiovascular risk assessment, thromboembolism, and infection prevention in Cushing\u2019s syndrome: a practical approach. Eur. J. Endocrinol. 184, R207\u2013R224 (2021).","journal-title":"Eur. J. Endocrinol."},{"key":"868_CR145","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1007\/s11102-022-01261-9","volume":"25","author":"RA Feelders","year":"2022","unstructured":"Feelders, R. A. & Nieman, L. K. Hypercoagulability in Cushing\u2019s syndrome: incidence, pathogenesis and need for thromboprophylaxis protocols. Pituitary 25, 746\u2013749 (2022).","journal-title":"Pituitary"},{"key":"868_CR146","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1007\/s00701-021-04823-1","volume":"163","author":"A Bunevicius","year":"2021","unstructured":"Bunevicius, A., Lavezzo, K., Smith, P. W., Vance, M. L. & Sheehan, J. Stereotactic radiosurgery before bilateral adrenalectomy is associated with lowered risk of Nelson\u2019s syndrome in refractory Cushing\u2019s disease patients. Acta Neurochir. 163, 1949\u20131956 (2021).","journal-title":"Acta Neurochir."},{"key":"868_CR147","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1007\/s40618-021-01531-6","volume":"44","author":"M Losa","year":"2021","unstructured":"Losa, M. et al. Gamma knife radiosurgery in patients with Nelson\u2019s syndrome. J. Endocrinol. Invest. 44, 2243\u20132251 (2021).","journal-title":"J. Endocrinol. Invest."},{"key":"868_CR148","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1093\/ejendo\/lvad008","volume":"188","author":"V Amodru","year":"2023","unstructured":"Amodru, V. et al. Cushing\u2019s syndrome in the elderly: data from the european registry on Cushing\u2019s syndrome. Eur. J. Endocrinol. 188, 395\u2013406 (2023).","journal-title":"Eur. J. Endocrinol."},{"key":"868_CR149","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1111\/cen.13799","volume":"89","author":"N Qiao","year":"2018","unstructured":"Qiao, N., Swearingen, B. & Tritos, N. A. Cushing\u2019s disease in older patients: presentation and outcome. Clin. Endocrinol. 89, 444\u2013453 (2018).","journal-title":"Clin. Endocrinol."},{"key":"868_CR150","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-022-02320-x","volume":"17","author":"FM van Haalen","year":"2022","unstructured":"van Haalen, F. M. et al. Current clinical practice for thromboprophylaxis management in patients with Cushing\u2019s syndrome across reference centers of the European Reference Network on rare endocrine conditions (Endo-ERN). Orphanet J. Rare Dis. 17, 178 (2022).","journal-title":"Orphanet J. Rare Dis."},{"key":"868_CR151","first-page":"3662","volume":"87","author":"M Boscaro","year":"2002","unstructured":"Boscaro, M. et al. Anticoagulant prophylaxis markedly reduces thromboembolic complications in Cushing\u2019s syndrome. J. Clin. Endocrinol. Metab. 87, 3662\u20133666 (2002).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"868_CR152","doi-asserted-by":"publisher","DOI":"10.1111\/jne.13142","volume":"34","author":"AJ Dekkers","year":"2022","unstructured":"Dekkers, A. J. et al. Long-term effects of glucocorticoid excess on the brain. J. Neuroendocrinol. 34, e13142 (2022).","journal-title":"J. Neuroendocrinol."},{"key":"868_CR153","doi-asserted-by":"publisher","first-page":"e3723","DOI":"10.1210\/clinem\/dgac379","volume":"107","author":"LT Braun","year":"2022","unstructured":"Braun, L. T. et al. Whom should we screen for cushing syndrome? the endocrine society practice guideline recommendations 2008 revisited. J. Clin. Endocrinol. Metab. 107, e3723\u2013e3730 (2022).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"868_CR154","doi-asserted-by":"publisher","first-page":"e4490","DOI":"10.1210\/clinem\/dgaa625","volume":"105","author":"F Vogel","year":"2020","unstructured":"Vogel, F. et al. Persisting muscle dysfunction in Cushing\u2019s syndrome despite biochemical remission. J. Clin. Endocrinol. Metab. 105, e4490\u2013e4498 (2020).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"868_CR155","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1007\/s11102-022-01245-9","volume":"25","author":"SM Webb","year":"2022","unstructured":"Webb, S. M. & Valassi, E. Quality of life impairment after a diagnosis of Cushing\u2019s syndrome. Pituitary 25, 768\u2013771 (2022).","journal-title":"Pituitary"},{"key":"868_CR156","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.ecl.2022.05.002","volume":"51","author":"N Gumaste","year":"2022","unstructured":"Gumaste, N., Shah, L., Cheesman, K. C. & Geer, E. B. Evaluating patient-reported outcomes in Cushing\u2019s syndrome. Endocrinol. Metab. Clin. North Am. 51, 691\u2013707 (2022).","journal-title":"Endocrinol. Metab. Clin. North Am."},{"key":"868_CR157","doi-asserted-by":"publisher","first-page":"934347","DOI":"10.3389\/fendo.2022.934347","volume":"13","author":"E Pupier","year":"2022","unstructured":"Pupier, E. et al. Impaired quality of life, but not cognition, is linked to a history of chronic hypercortisolism in patients with Cushing\u2019s disease in remission. Front. Endocrinol. 13, 934347 (2022).","journal-title":"Front. Endocrinol."},{"key":"868_CR158","doi-asserted-by":"publisher","first-page":"e2035","DOI":"10.1210\/clinem\/dgab058","volume":"106","author":"MH Schernthaner-Reiter","year":"2021","unstructured":"Schernthaner-Reiter, M. H. et al. Acute and life-threatening complications in cushing syndrome: prevalence, predictors, and mortality. J. Clin. Endocrinol. Metab. 106, e2035\u2013e2046 (2021).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"868_CR159","doi-asserted-by":"publisher","first-page":"e2921","DOI":"10.1210\/clinem\/dgac174","volume":"107","author":"A Ebbehoj","year":"2022","unstructured":"Ebbehoj, A. et al. The socioeconomic consequences of Cushing\u2019s syndrome: a nationwide cohort study. J. Clin. Endocrinol. Metab. 107, e2921\u2013e2929 (2022).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"868_CR160","doi-asserted-by":"publisher","first-page":"862","DOI":"10.3389\/fendo.2019.00862","volume":"10","author":"A Santos","year":"2019","unstructured":"Santos, A. et al. Quality of life in patients with Cushing\u2019s disease. Front. Endocrinol. 10, 862 (2019).","journal-title":"Front. Endocrinol."},{"key":"868_CR161","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1210\/jc.2004-1375","volume":"90","author":"MO van Aken","year":"2005","unstructured":"van Aken, M. O. et al. Quality of life in patients after long-term biochemical cure of Cushing\u2019s disease. J. Clin. Endocrinol. Metab. 90, 3279\u20133286 (2005).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"868_CR162","doi-asserted-by":"publisher","DOI":"10.1111\/jne.13118","volume":"34","author":"R Hamblin","year":"2022","unstructured":"Hamblin, R., Coulden, A., Fountas, A. & Karavitaki, N. The diagnosis and management of Cushing\u2019s syndrome in pregnancy. J. Neuroendocrinol. 34, e13118 (2022).","journal-title":"J. Neuroendocrinol."},{"key":"868_CR163","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1007\/s11102-021-01142-7","volume":"24","author":"K Sridharan","year":"2021","unstructured":"Sridharan, K. et al. Diagnosis and treatment outcomes of Cushing\u2019s disease during pregnancy. Pituitary 24, 670\u2013680 (2021).","journal-title":"Pituitary"},{"key":"868_CR164","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1530\/EJE-20-1224","volume":"184","author":"C Hochman","year":"2021","unstructured":"Hochman, C. et al. Pre-term birth in women exposed to Cushing\u2019s disease: the baby-cush study. Eur. J. Endocrinol. 184, 469\u2013476 (2021).","journal-title":"Eur. J. Endocrinol."},{"key":"868_CR165","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EJE-21-0462","volume":"185","author":"A Luger","year":"2021","unstructured":"Luger, A. et al. ESE clinical practice guideline on functioning and nonfunctioning pituitary adenomas in pregnancy. Eur. J. Endocrinol. 185, G1\u2013G33 (2021).","journal-title":"Eur. J. Endocrinol."},{"key":"868_CR166","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1111\/cen.13600","volume":"88","author":"E Valassi","year":"2018","unstructured":"Valassi, E. et al. Worse health-related quality of life at long-term follow-up in patients with Cushing\u2019s disease than patients with cortisol producing adenoma. Data from the ERCUSYN. Clin. Endocrinol. 88, 787\u2013798 (2018).","journal-title":"Clin. Endocrinol."},{"key":"868_CR167","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1530\/EJE-19-0464","volume":"181","author":"E Valassi","year":"2019","unstructured":"Valassi, E. et al. High mortality within 90 days of diagnosis in patients with Cushing\u2019s syndrome: results from the ERCUSYN registry. Eur. J. Endocrinol. 181, 461\u2013472 (2019).","journal-title":"Eur. J. Endocrinol."},{"key":"868_CR168","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1210\/jc.2012-2893","volume":"98","author":"JK Lambert","year":"2013","unstructured":"Lambert, J. K. et al. Predictors of mortality and long-term outcomes in treated Cushing\u2019s disease: a study of 346 patients. J. Clin. Endocrinol. Metab. 98, 1022\u20131030 (2013).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"868_CR169","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1007\/s11102-013-0503-3","volume":"17","author":"M Boscaro","year":"2014","unstructured":"Boscaro, M. et al. Extended treatment of Cushing\u2019s disease with pasireotide: results from a 2-year, phase II study. Pituitary 17, 320\u2013326 (2014).","journal-title":"Pituitary"},{"key":"868_CR170","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1007\/s11102-014-0618-1","volume":"18","author":"J Schopohl","year":"2015","unstructured":"Schopohl, J. et al. Pasireotide can induce sustained decreases in urinary cortisol and provide clinical benefit in patients with Cushing\u2019s disease: results from an open-ended, open-label extension trial. Pituitary 18, 604\u2013612 (2015).","journal-title":"Pituitary"},{"key":"868_CR171","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1055\/s-0042-101347","volume":"48","author":"L Trementino","year":"2016","unstructured":"Trementino, L. et al. A single-center 10-year experience with pasireotide in Cushing\u2019s disease: patients\u2019 characteristics and outcome. Horm. Metab. Res. 48, 290\u2013298 (2016).","journal-title":"Horm. Metab. Res."},{"key":"868_CR172","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1007\/s12020-017-1316-3","volume":"57","author":"S Petersenn","year":"2017","unstructured":"Petersenn, S. et al. Long-term treatment of Cushing\u2019s disease with pasireotide: 5-year results from an open-label extension study of a phase III trial. Endocrine 57, 156\u2013165 (2017).","journal-title":"Endocrine"},{"key":"868_CR173","doi-asserted-by":"publisher","first-page":"436","DOI":"10.3389\/fendo.2019.00436","volume":"10","author":"M Fleseriu","year":"2019","unstructured":"Fleseriu, M. et al. Safety and efficacy of subcutaneous pasireotide in patients with Cushing\u2019s disease: results from an open-label, multicenter, single-arm, multinational, expanded-access study. Front. Endocrinol. 10, 436 (2019).","journal-title":"Front. Endocrinol."},{"key":"868_CR174","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1007\/s12020-018-1818-7","volume":"64","author":"R Pivonello","year":"2019","unstructured":"Pivonello, R. et al. The medical treatment with pasireotide in Cushing\u2019s disease: an Italian multicentre experience based on \u201creal-world evidence\u201d. Endocrine 64, 657\u2013672 (2019).","journal-title":"Endocrine"},{"key":"868_CR175","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1530\/EJE-10-0382","volume":"163","author":"A Godbout","year":"2010","unstructured":"Godbout, A. et al. Cabergoline monotherapy in the long-term treatment of Cushing\u2019s disease. Eur. J. Endocrinol. 163, 709\u2013716 (2010).","journal-title":"Eur. J. Endocrinol."},{"key":"868_CR176","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1210\/jc.2008-1533","volume":"94","author":"R Pivonello","year":"2009","unstructured":"Pivonello, R. et al. The medical treatment of Cushing\u2019s disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery. J. Clin. Endocrinol. Metab. 94, 223\u2013230 (2009).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"868_CR177","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1007\/s11102-015-0692-z","volume":"19","author":"M Fleseriu","year":"2016","unstructured":"Fleseriu, M. et al. Osilodrostat, a potent oral 11beta-hydroxylase inhibitor: 22-week, prospective, phase II study in Cushing\u2019s disease. Pituitary 19, 138\u2013148 (2016).","journal-title":"Pituitary"},{"key":"868_CR178","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s11060-019-03325-6","volume":"145","author":"A Bunevicius","year":"2019","unstructured":"Bunevicius, A., Laws, E. R., Vance, M. L., Iuliano, S. & Sheehan, J. Surgical and radiosurgical treatment strategies for Cushing\u2019s disease. J. Neurooncol. 145, 403\u2013413 (2019).","journal-title":"J. Neurooncol."}],"container-title":["Nature Reviews Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41574-023-00868-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41574-023-00868-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41574-023-00868-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T09:06:43Z","timestamp":1694423203000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41574-023-00868-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,3]]},"references-count":178,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["868"],"URL":"https:\/\/doi.org\/10.1038\/s41574-023-00868-7","relation":{},"ISSN":["1759-5029","1759-5037"],"issn-type":[{"value":"1759-5029","type":"print"},{"value":"1759-5037","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,3]]},"assertion":[{"value":"22 June 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.F. has received grants to the institution from Crinetics, Novartis, Recordati, Sparrow, and Xeris (formerly Strongbridge), consulting fees from Crinetics, HRA Pharma, Novartis, Recordati, Sparrow, and Xeris (formerly Strongbridge), and serves as a member of the Board of Directors (non-compensated) for the Pituitary Society. E.V.V. has received grants to the institution from Recordati. F.L. has served as an adviser to Novartis and Recordati, and has served as a member of the Continuing Medical Education Committee for AMEQ (Association des M\u00e9decins Endocrinologues du Qu\u00e9bec). S.M. has received grants to the institution from the US Food and Drug Administration and Recordati and non-financial support from Cyclacel, and serves as Secretary (non-compensated) for the Pituitary Society. J.M.H.-A. declares no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}